Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Liabilities and Shareholders Equity (2020 - 2025)

Pulse Biosciences (PLSE) has 6 years of Liabilities and Shareholders Equity data on record, last reported at $94.5 million in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 28.63% year-over-year to $94.5 million; the TTM value through Dec 2025 reached $456.9 million, up 45.01%, while the annual FY2025 figure was $94.5 million, 28.63% down from the prior year.
  • Liabilities and Shareholders Equity reached $94.5 million in Q4 2025 per PLSE's latest filing, down from $108.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $133.4 million in Q1 2025 and bottomed at $39.5 million in Q1 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $78.7 million, with a median of $76.3 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: crashed 50.92% in 2022, then soared 197.44% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $59.2 million in 2021, then surged by 31.65% to $77.9 million in 2022, then dropped by 24.04% to $59.2 million in 2023, then soared by 123.92% to $132.5 million in 2024, then dropped by 28.63% to $94.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $94.5 million in Q4 2025, $108.8 million in Q3 2025, and $120.3 million in Q2 2025.